Personalized mRNA Vaccine Is Feasible and Immunogenic in …
A personalized neoantigen-specific immunotherapy vaccine is immunogenic in pancreatic ductal adenocarcinoma (PDAC) and can be manufactured in real time and delivered in a median of 9 weeks following surgery, according to findings from an investigator-initiated phase 1 trial ( Abstract 2516 ). The individualized mRNA-based …